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Abstract 
Background: Infection during pregnancy with Plasmodium falciparum is associated with maternal anaemia and 
adverse birth outcomes including low birth weight (LBW). Studies using polymerase chain reaction (PCR) techniques 
indicate that at least half of all infections in maternal venous blood are missed by light microscopy or rapid diagnostic 
tests. The impact of these subpatent infections on maternal and birth outcomes remains unclear.
Methods: In a cohort of women co‑enrolled in a clinical trial of intermittent treatment with sulfadoxine–pyrimeth‑
amine (SP) plus azithromycin for the prevention of LBW (< 2500 g) in Papua New Guinea (PNG), P. falciparum infection 
status at antenatal enrolment and delivery was assessed by routine light microscopy and real‑time quantitative PCR. 
The impact of infection status at enrolment and delivery on adverse birth outcomes and maternal haemoglobin at 
delivery was assessed using logistic and linear regression models adjusting for potential confounders. Together with 
insecticide‑treated bed nets, women had received up to 3 monthly intermittent preventive treatments with SP plus 
azithromycin or a single clearance treatment with SP plus chloroquine.
Results: A total of 9.8% (214/2190) of women had P. falciparum (mono‑infection or mixed infection with Plasmodium 
vivax) detected in venous blood at antenatal enrolment at 14–26 weeks’ gestation. 4.7% of women had microscopic, 
and 5.1% submicroscopic P. falciparum infection. At delivery (n = 1936), 1.5% and 2.0% of women had submicroscopic 
and microscopic P. falciparum detected in peripheral blood, respectively. Submicroscopic P. falciparum infections at 
enrolment or at delivery in peripheral or placental blood were not associated with maternal anaemia or adverse birth 
outcomes such as LBW. Microscopic P. falciparum infection at antenatal enrolment was associated with anaemia at 
delivery (adjusted odds ratio [aOR] 2.00, 95% confidence interval [CI] 1.09, 3.67; P = 0.025). Peripheral microscopic P. 
falciparum infection at delivery was associated with LBW (aOR 2.75, 95% CI 1.27; 5.94, P = 0.010) and preterm birth 
(aOR 6.58, 95% CI 2.46, 17.62; P < 0.001).
Conclusions: A substantial proportion of P. falciparum infections in pregnant women in PNG were submicroscopic. 
Microscopic, but not submicroscopic, infections were associated with adverse outcomes in women receiving malaria 
preventive treatment and insecticide‑treated bed nets. Current malaria prevention policies that combine insecticide‑
treated bed nets, intermittent preventive treatment and prompt treatment of symptomatic infections appear to be 
appropriate for the management of malaria in pregnancy in settings like PNG.
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Background
Infection with the malaria parasite Plasmodium falci-
parum during pregnancy is detrimental to both mother 
and the developing fetus. It causes maternal anaemia and 
can lead to significant maternal morbidity and death, in 
particular in low-transmission settings [1]. Sequestra-
tion of P. falciparum-infected erythrocytes in the pla-
cental intervillous space disturbs transplacental nutrient 
transport and creates a reservoir of inflammation [2]. As 
a consequence, infected mothers are also more likely to 
deliver low birth weight babies (LBW; < 2500  g) [1, 3]. 
Therefore, P. falciparum infection is a principal cause 
of LBW and infant death in endemic settings [3]. LBW, 
which can be due to preterm birth (PTB) and/or fetal 
growth restriction, has significant short and long-term 
negative impacts [4].
Whilst light microscopy (LM) and/or rapid diagnostic 
tests are used in clinical practice to detect infection in 
women self-presenting to health facilities with symptoms, 
research studies using sensitive polymerase chain reac-
tion (PCR) techniques have helped to unravel the true 
burden of infection in pregnancy. Many of these stud-
ies suggest that at least half of P. falciparum infections 
in peripheral maternal blood are missed by LM [5–10]. 
Submicroscopic P. falciparum infections were associated 
with maternal anaemia [5, 9, 10] and LBW [5, 8, 11, 12] 
in some but not all studies [6, 7, 13]. The impact of sub-
microscopic placental P. falciparum infections is less well 
described but limited evidence suggests these are associ-
ated with LBW [12]. Mixed P. falciparum/Plasmodium 
vivax submicroscopic infections may be associated with 
PTB, but submicroscopic P. vivax mono-infections were 
not associated with anaemia or LBW [13, 14]. Monthly 
intermittent preventive treatment of malaria in preg-
nancy with sulfadoxine–pyrimethamine (SP), a strategy 
implemented to treat occult placental infection, clears 
submicroscopic P. falciparum infections but does not 
prevent re-infection in the interval between treatments 
[6].
The present study evaluates the associations between 
microscopic and submicroscopic P. falciparum infections 
at antenatal enrolment and at delivery and maternal hae-
moglobin at delivery or adverse pregnancy outcomes in a 
cohort of pregnant Papua New Guinean (PNG) women. 
Participants were co-enrolled in a clinical trial evalu-
ating intermittent preventive treatment with SP plus 
azithromycin (SPAZ) for the prevention of LBW. Adverse 
pregnancy outcomes assessed included LBW, PTB 
(< 37 weeks of gestation) and measuring small-for-gesta-
tional age at birth as a proxy for fetal growth restriction.
Methods
Study design and setting
A prospective cohort study of pregnant women was 
undertaken from November 2009 until February 2013 
at nine antenatal clinics and health centres in Madang 
Province on the North Coast of PNG. Women’s malaria 
infection status was assessed by quantitative real-time 
PCR and LM at study inclusion, and participants were 
followed up for birth outcomes including miscarriage, 
stillbirth, LBW, PTB and fetal growth restriction, and 
maternal haemoglobin was measured at delivery. Mater-
nal malaria infection status was assessed at delivery using 
peripheral and placental blood. A subset of women had 
microscopy and PCR examination of peripheral blood 
at their second and third antenatal study visits (1 and 
2  months following the enrolment visit, respectively) to 
assess point prevalence.
The study setting has been described in detail previ-
ously [15]. In brief, there is perennial transmission of 
both P. falciparum and P. vivax and a high burden of 
adverse pregnancy outcomes, particularly LBW (17%) 
and maternal anaemia (90% of pregnant women had a 
haemoglobin < 110  g/L) [8]. Women in the cohort study 
were co-enrolled in a clinical trial assessing the impact of 
3 monthly intermittent preventive treatments with SPAZ 
on LBW [15]. Whenever possible, women were provided 
with insecticide-treated bed nets and given oral iron 
and folic acid supplementation, as per national policy. 
The estimated antenatal HIV prevalence in the region 
was 1%. Women not randomized to SPAZ received the 
control treatment (single malaria clearance treatment 
at study inclusion with SP plus chloroquine) as per cur-
rent national policy. Multiple pregnancies and women 
with an estimated gestational age greater than 26 gesta-
tional weeks by symphysis-fundal height were excluded. 
The parent trial demonstrated that SPAZ significantly 
reduced the risks of LBW and PTB [15].
Clinical assessments
Birth weights were measured using digital infant scales 
(Cupid 1, Charder Medical, Taiwan; accuracy 10  g). 
Pregnancy losses before an estimated 22 gestational 
weeks were categorized as miscarriages. Haemoglobin 
levels were estimated using by HemoCue (Angelholm, 
Sweden; accuracy of 1  g/L). Anaemia was defined as a 
Keywords: Anaemia, Diagnosis, Fetal growth retardation, Low birth weight, Malaria, Plasmodium falciparum, 
Pregnancy outcome, Premature birth
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haemoglobin < 110 g/L. A sub-set of women in the study 
underwent ultrasound dating of their pregnancy (Logiq-
book XP, General Electric Medical Systems, UK), as 
described previously [15]. Birth before 37 gestational 
weeks was defined as PTB. Small-for-gestational age 
(SGA) was defined as a birth weight below the 10th cen-
tile of the Intergrowth-21 standard [16].
Laboratory analysis
Maternal peripheral blood smears were prepared from 
venous blood samples taken at enrolment and at deliv-
ery. Air-dried blood smears were stained for 30 min with 
4% Giemsa. The number of asexual parasites per 200 
leukocytes (or per 500 if < 10 parasites/200 leukocytes) 
were counted on thick blood smear, assuming 8000  leu-
kocytes/μL of blood. Smears were judged negative fol-
lowing examination of 200 oil-immersion fields without 
detection of parasites. Each slide was assessed by two 
microscopists, and discrepant results were resolved by 
third reads, or when necessary, by qPCR [17]. qPCR was 
used to detect P. falciparum and P. vivax infections in 
maternal venous blood samples collected in EDTA anti-
coagulant. DNA was extracted from 200 μL whole blood 
with QIAamp96 DNA Blood Mini Kit (QIAGEN, Valen-
cia, CA) and eluted to a final volume of 200 μL dH20, and 
analysed as previously described (qPCR sensitivity: 1 par-
asite per μL) [18].
For each infection assessment P. falciparum infection 
status was coded ‘negative’ if both LM and qPCR were 
negative for P. falciparum, ‘submicroscopic infection’ if 
the thick smear was negative but qPCR detected P. fal-
ciparum, and ‘microscopic infection’ if both thick smear 
and qPCR detected P. falciparum. Women with incom-
plete data for LM and qPCR at study inclusion, and 
women with positive LM but negative qPCR (i.e. possible 
Plasmodium ovale/Plasmodium malariae infections or 
false positive smears), were excluded from the study.
Statistical analysis
Linear regression models were designed to assess the 
association between P. falciparum infection status, classi-
fied as submicroscopic infection versus no infection or as 
microscopic infection versus no infection, and continu-
ous parametric outcome measures (birth weight, haemo-
globin). Logistic regression models were constructed to 
assess the association between P. falciparum infection 
status and bivariate outcome measures (pregnancy loss, 
LBW, PTB, SGA and anaemia).
All singleton pregnancies with complete LM/qPCR 
data at study inclusion that were successfully followed up 
for birth outcome were considered in the pregnancy loss 
analysis. Birth weight analyses were confined to singleton 
congenitally normal live born babies for whom a birth 
weight measurement was available.
Analyses of pregnancy outcomes were adjusted a priori 
for factors previously identified as determinants of birth 
weight in the cohort, namely treatment arm of the parent 
clinical trial, sex of the baby, gravidity, number of study 
visits, enrolment clinic, bed net use, maternal nutritional 
status, stunting, and socio-economic status, and timing 
of birth weight measurement (not included as covari-
ate in PTB analyses) [15]. Haemoglobin analyses were 
adjusted a priori for treatment arm, gravidity, betel nut 
consumption, number of study visits, enrolment clinic, 
bed net use, nutritional status, stunting, socio-economic 
status and timing of haemoglobin measurement [19].
Plasmodium falciparum infections included mono-
infections and dual infections with P. vivax. Plasmodium 
vivax mono-infections were not associated with any of 
the adverse outcomes under scrutiny in this study or in a 
published multi-centre observational study to which part 
of the present cohort contributed [14], and analyses were 
thus not adjusted for their presence.
Analyses were conducted separately for infection sta-
tus at enrolment (prospective cohort study) and infection 
status at delivery (cross-sectional analysis). In view of the 
fact that only half of women had infection status assess-
ments at second and third study visits, and given compar-
atively the low infection prevalence at these time points, 
these data not included in outcome analyses but are pre-
sented to describe infection prevalence between the first 
antenatal visit and delivery. In addition, associations were 
assessed between infection status at both enrolment and 
delivery combined, and analyses were performed strati-
fied on gravidity. A P-value < 0.05 was considered sta-
tistically significant. Findings are presented in line with 
guidance for the reporting of observational studies.
Ethical considerations
The study was approved by the PNG Institute of Medical 
Research (PNGIMR) Institutional Review Board (0815), 
the PNG Medical Research Advisory Council (08.01), and 
the Melbourne Health Human Research Ethics Commit-
tee (2008.162). The study was conducted in accordance 
with Good Clinical Practice guidelines (ICH GCP E6).
Results
Of 2793 women enrolled in the parent clinical trial, 2190 
had singleton pregnancies and complete LM/qPCR data 
at inclusion and were successfully followed up for birth 
outcome. Amongst them, 1976 babies were suitable for 
inclusion in the birth weight analysis, and 1832 women 
had their haemoglobin levels measured at birth (Fig. 1).
The mean gestational age at enrolment by symphysis-
fundal height was 21.1  weeks (standard deviation [SD], 
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Fig. 1 Study flowchart. LM light microscopy, PCR polymerase‑chain reaction
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4.2 weeks), 49.0% of women were primigravid, and 50.3% 
were randomized to SPAZ.
A total of 9.8% (n = 214) of women had P. falciparum 
detected in venous blood at enrolment and (n = 61) of 
women had P. vivax mono-infections (Table 1). Plasmo-
dium falciparum infection prevalence at interim ante-
natal visits, assessed in a subset of women only, was low 
(Table  1). At delivery 3.5% of women had P. falciparum 
infection detected in peripheral venous blood, and 4.4% 
in placental blood (Table 1). Only 11 women (0.6%) had 
P. falciparum infections detected in peripheral blood at 
both enrolment and delivery.
There were 40 stillbirths and 10 miscarriages. 
Amongst women with a congenitally normal live birth 
and who were followed up for birth weight (n = 1976), 
15.2% (n = 301) of babies were LBW and mean birth 
weight was 2943  g (SD 477). Ultrasound dating was 
undertaken for 1294 (65.5%) of these pregnancies: 
9.3% and 24.7% of babies were born preterm and SGA, 
respectively. The mean haemoglobin at delivery was 
100.5  g/L (SD 17). Three quarters of women (74.2%, 
n = 1360) were anaemic at delivery.
Plasmodium falciparum infection at first antenatal visit 
and adverse pregnancy outcomes
Submicroscopic and microscopic P. falciparum infections 
were not associated with stillbirth or miscarriage, LBW, 
PTB and SGA (Table 2). The adjusted mean birth weight 
difference was − 2 g (95% confidence interval [CI] − 94, 
90; P = 0.97) for submicroscopic P. falciparum infection, 
and − 12 g (95% CI − 108, 83; P = 0.80) for microscopic 
infection.
Peripheral and placental P. falciparum infection at delivery 
and adverse pregnancy outcomes
Microscopic but not submicroscopic P. falciparum infec-
tions at delivery were associated with LBW and PTB in 
the cohort (Table  3). The association between micro-
scopic infection at enrolment and LBW was more pro-
nounced amongst primigravid (aOR 3.49; 95% CI 1.35, 
9.04) compared to multigravid women (aOR 2.31, 95% CI 
0.75, 7.14). The adjusted mean birth weight difference was 
− 48 g (95% CI − 214, 118; P = 0.57) for submicroscopic, 
Table 1 Point prevalence malaria infection at study visits
a  P. falciparum mono-infection or mixed infection with P. vivax (n = 12)
b  P. falciparum mono-infection or mixed infection with P. vivax (n = 1)
Study visit No infection
% (n)
Submicroscopic 
infection
% (n)
Microscopic 
infection
% (n)
Enrolment (n = 2190)
 P. falciparuma 90.2 (1976) 5.1 (111) 4.7 (103)
 P. vivax mono‑
infection
97.2 (2129) 2.2 (48) 0.6 (13)
Second study visit (n = 1015)
 P. falciparum 98.5 (1000) 0.7 (7) 0.8 (8)
Third study visit (n = 859)
 P. falciparum 97.8 (841) 1.1 (9) 1.1 (9)
Delivery—peripheral blood (n = 1936)
 P. falciparum 96.5 (1869) 1.5 (29) 2.0 (38)
 P. vivax mono‑
infection
98.3 (1904) 1.6 (30) 0.1 (2)
Delivery—placental blood (n = 1300)
 P. falciparumb 96.6 (1256) 1.1 (14) 2.3 (30)
 P. vivax mono‑
infection
99.5 (1293) 0.5 (7) 0.0 (0)
Table 2 Associations between  Plasmodium falciparum 
infection at  antenatal enrolment and  miscarriage/
stillbirth, low birthweight, preterm birth and fetal growth 
restriction
a  Adjusted for treatment arm, gravidity, enrolment clinic, bed net use, 
undernutrition, stunting, ethnicity and socio-economic status
b  Adjusted for treatment arm, gender of the baby, gravidity, number of study 
visits, enrolment clinic, bed net use, nutritional status, stunting, socio-economic 
status and timing of birthweight measurement
c  Adjusted for treatment arm, gender of the baby, gravidity, number of study 
visits, enrolment clinic, bed net use, nutritional status, stunting, and socio-
economic status
Infection status % (N/N total) Adjusted 
odds 
ratio
95% 
confidence 
interval
P
Miscarriage/stillbirtha (n = 2190)
 No infection 2.2 (44/1976)
 Submicroscopic 
infection
1.8 (2/111) 0.81 (0.19, 3.41) 0.77
 Microscopic infec‑
tion
3.9 (4/103) 1.96 (0.68, 5.66) 0.22
Low  birthweightb (n = 1976)
 No infection 15.1 (270/1786)
 Submicroscopic 
infection
14.3 (14/98) 1.01 (0.55, 1.84) 0.98
 Microscopic infec‑
tion
18.5 (17/92) 0.97 (0.54, 1.75) 0.93
Preterm  birthc (n = 1294)
 No infection 8.9 (105/1181)
 Submicroscopic 
infection
1.7 (1/60) 0.17 (0.02, 1.26) 0.08
 Microscopic infec‑
tion
11.3 (6/53) 1.22 (0.49, 1.26) 0.67
Small for gestational  ageb (n = 1294)
 No infection 24.5 (289/1181)
 Submicroscopic 
infection
33.3 (20/60) 1.65 (0.93, 2.92) 0.09
 Microscopic infec‑
tion
20.8 (11/53) 0.71 (0.35, 1.43) 0.34
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and − 126  g (95% CI − 273, 20.8; P = 0.09) for micro-
scopic P. falciparum infection.
The adjusted mean birth weight difference for placental 
submicroscopic infection was − 179 g (95% CI − 417, 60; 
P = 0.14), and for placental microscopic infection − 154 g 
(95% CI − 320, 11; P = 0.07). Neither microscopic nor 
submicroscopic placental P. falciparum infection was sig-
nificantly associated with LBW, PTB or SGA (Table 3).
Plasmodium falciparum infection and anaemia at delivery
Women with microscopic but not submicroscopic P. fal-
ciparum infection at enrolment were more likely to be 
anaemic at delivery compared to women with no infec-
tion (Table  4). The association between microscopic 
infection at enrolment and anaemia at delivery was more 
pronounced amongst multigravid (aOR 2.41; 95% CI 1.12, 
5.17) compared to primigravid women (aOR 1.92, 95% 
CI 0.74, 5.00). The adjusted mean difference in maternal 
haemoglobin at delivery by infection status at enrolment 
was -0.7  g/L (95% CI − 4.3, 2.9; P = 0.69) for submicro-
scopic P. falciparum infection, and − 2.6 (95% CI − 6.1, 
1.1; P = 0.17) for microscopic P. falciparum infection.
For parasitaemia at delivery, the adjusted mean differ-
ence for maternal haemoglobin at delivery was − 2.5 g/L 
(95% CI − 9.4, 4.3; P = 0.47) for submicroscopic P. fal-
ciparum infection, and − 5.9  g/L (95% CI − 11.8, 0.1; 
P = 0.05) for microscopic infection. There was no sta-
tistically significant increase in the odds of anaemia in 
women with microscopic and submicroscopic P. falcipa-
rum infection at delivery compared to women with no 
infection (Table 4).
For placental malaria, the adjusted mean difference for 
maternal haemoglobin at delivery was − 1.1 g/L (95% CI 
− 10.1, 7.8; P = 0.80) for submicroscopic P. falciparum 
infection, and − 6.2 g/L (95% CI − 13.2, 7.8; P = 0.09) for 
Table 3 Association of  microscopic and  submicroscopic Plasmodium falciparum infection at  delivery in  maternal 
peripheral venous blood and placental blood with low birthweight, preterm birth and fetal growth restriction
a  Adjusted for treatment arm, gender of the baby, gravidity, number of study visits, enrolment clinic, bed net use, nutritional status, stunting, socio-economic status 
and timing of birthweight measurement
b  Adjusted for treatment arm, gender of the baby, gravidity, number of study visits, enrolment clinic, bed net use, nutritional status, stunting, and socio-economic 
status
Infection status % (N/N total) Adjusted odds ratio 95% confidence interval P
P. falciparum infection at delivery (peripheral blood)
 Low  birthweighta (n = 1878)
  No infection 15.0 (272/1812)
  Submicroscopic infection 17.2 (5/29) 1.00 (0.35, 2.83) 0.99
  Microscopic infection 29.7 (11/37) 2.75 (1.27, 5.94) 0.010
 Preterm  birthb (n = 1229)
  No infection 8.2 (97/1190)
  Submicroscopic infection 5.9 (1/17) 0.54 (0.07, 4.29) 0.56
  Microscopic infection 31.8 (7/22) 6.58 (2.46, 17.62) < 0.001
 Small for gestational  agea (n = 1229)
  No infection 24.1 (287/1190)
  Submicroscopic infection 29.4 (5/17) 1.32 (0.44, 3.96) 0.63
  Microscopic infection 31.8 (7/22) 1.71 (0.67, 4.39) 0.26
P. falciparum infection at delivery (placental blood)
 Low  birthweighta (n = 1272)
  No infection 13.8 (170/1228)
  Submicroscopic infection 28.6 (4/14) 2.85 (0.82, 9.91) 0.10
  Microscopic infection 30.0 (9/30) 2.08 (0.87, 4.98) 0.10
 Preterm  birthb (n = 781)
  No infection 6.9 (52/749)
  Submicroscopic infection 18.2 (2/11) 3.34 (0.66, 16.83) 0.15
  Microscopic infection 19.1 (4/21) 3.04 (0.89, 10.3) 0.08
 Small for gestational  agea (n = 781)
  No infection 21.4 (160/749)
  Submicroscopic infection 36.4 (4/11) 2.60 (0.71, 9.56) 0.15
  Microscopic infection 33.3 (7/21) 1.62 (0.61, 4.34) 0.34
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microscopic infection. Placental P. falciparum infection 
was not significantly associated with maternal anaemia at 
delivery (Table 4).
Association of infection at enrolment with infection 
at delivery
There was no association between P. falciparum infection 
(submicroscopic or microscopic) at antenatal enrolment 
with peripheral blood infection at delivery (P = 0.42). 
Microscopic infection at enrolment (P < 0.001), but not 
submicroscopic (P = 0.38) infection was associated with 
P. falciparum infection in placental blood. When periph-
eral P. falciparum infection at enrolment and delivery 
were combined, microscopic infection was associated 
with preterm birth (aOR 2.54, CI 1.30–4.97, P =  0.006, 
Additional file 1)
Discussion
In this cohort of PNG women receiving at least one dose 
of SP-IPTp submicroscopic P. falciparum infections 
detected at first antenatal visit (~ 14–26 weeks of gesta-
tion) or at delivery were not associated with maternal 
anaemia or adverse birth outcomes such as LBW. Periph-
eral microscopic P. falciparum infection at antenatal 
enrolment was associated with anaemia at delivery, and 
at delivery it was associated with LBW and PTB. LM 
underestimated infection prevalence at first antenatal 
visit by more than 50%.
The relationship between submicroscopic P. falcipa-
rum and pregnancy outcomes remains contentious, and 
the present study is not the only one to report an appar-
ent lack of association between submicroscopic periph-
eral infection and adverse maternal [7, 13] and infant 
outcomes at birth [6, 13, 20]. Studies demonstrating no 
association are characterized by a comparatively low 
infection burden, suggesting lack of power may be an 
issue. Other factors, such as differences in malaria pre-
vention approaches, ethnic differences, proportion of 
primigravidae in the sample, transmission intensity, and 
the type of PCR assay used, may play a role. In women 
not receiving or defaulting from IPTp the burden of sub-
microscopic infections will be higher and such infec-
tions are likely to develop into higher density and chronic 
infections, both of which are associated with adverse 
outcomes. Individual participant data meta-analysis 
may reveal the true impact of submicroscopic infections 
and could account for some of the foregoing factors. In 
contrast to another study [12], placental microscopic 
and submicroscopic infection were not associated with 
adverse outcomes, although there were trends towards a 
deleterious effect for both infection categories.
Neither microscopic or submicroscopic P. falciparum 
infection detected at study inclusion were associated 
with adverse birth outcomes, suggesting anti-malarial 
treatments given as part of the clinical trial cleared most 
infections or reduced parasite densities and limited del-
eterious downstream effects. Microscopic infections 
detected in peripheral blood at delivery were associated 
with adverse birth outcomes, re-affirming the deleterious 
impact of microscopic P. falciparum infection for both 
mother and fetus. Such late infections may represent 
recrudescence, or new infections acquired in later preg-
nancy. Indeed, the proportion of women infected with P. 
falciparum fell following study enrolment and first treat-
ment, remaining low at second and third treatment vis-
its, but resurged at delivery, as reported from another 
Table 4 Association of  Plasmodium falciparum infection at  antenatal enrolment and  at  delivery and  anaemia 
(haemoglobin < 110 g/L) at delivery
a  Adjusted for treatment arm, gravidity, betel nut consumption, number of study visits, enrolment clinic, bed net use, nutritional status, stunting, socio-economic 
status and timing of haemoglobin measurement
Infection status % (N/N total) Adjusted odds  ratioa 95% confidence interval P
P. falciparum infection at enrolment (n = 1832)
 No infection 73.9 (1218/1649)
 Submicroscopic infection 69.2 (63/91) 0.78 (0.49, 1.24) 0.29
 Microscopic infection 85.9 (79/92) 2.00 (1.09, 3.67) 0.025
P. falciparum infection at delivery (peripheral blood) (n = 1756)
 No infection 74.2 (1261/1700)
 Submicroscopic infection 79.2 (19/24) 1.15 (0.42, 3.16) 0.79
 Microscopic infection 78.1 (25/32) 1.15 (0.49, 2.72) 0.75
P. falciparum infection at delivery (placental blood) (n = 1174)
 No infection 71.7 (815/1137)
 Submicroscopic infection 71.4 (10/14) 0.87 (0.27, 2.81) 0.81
 Microscopic infection 78.3 (18/23) 1.28 (0.47, 3.53) 0.63
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longitudinal study [5]. Many study participants did 
not receive anti-malarials in the last 2  months of preg-
nancy, and this finding supports the policy of continuing 
monthly IPTp until delivery.
Microscopic but not submicroscopic infection was 
associated with anaemia at delivery. Akin to birth out-
comes there is heterogeneity in the reported impact of 
submicroscopic P. falciparum on maternal anaemia. The 
apparent lack of association between submicroscopic 
P. falciparum and anaemia in this study may be due to 
relatively low infection prevalence and sample size, and 
potential confounders such as iron and folic acid supple-
mentation, prescribed to all study participants, may be of 
importance.
Plasmodium vivax mono-infections, most of which 
were submicroscopic, were not associated with any of 
the adverse outcomes assessed in this cohort, reflecting 
findings from a recent multi-centre study which included 
a subset of women from this cohort in their analyses 
[14]. Research from Colombia found an increased risk 
of PTB amongst women with submicroscopic mixed P. 
falciparum/P. vivax infection, but not P. vivax or P. fal-
ciparum submicroscopic mono-infections [13]. The small 
number of mixed infections in the present cohort pre-
cluded a meaningful assessment of their impact and they 
were consequently grouped together with P. falciparum 
mono-infections in the analyses.
The strengths of this study include its large sample 
size, longitudinal design and assessment of infection at 
enrolment and in both peripheral and placental blood at 
delivery. Important limitations include the lack of para-
site genotyping data to distinguish recrudescent from 
novel infections, the lack of obstetric ultrasound for a 
third of pregnancies, and the comparatively low infec-
tion burden, potentially affecting power of the study to 
detect associations between infection and adverse out-
comes. The sample size of the present study was based 
on power calculations in relation to the impact of the 
trial intervention on outcomes rather than infection sta-
tus, and infection burden was lower than anticipated at 
trial design. The authors recognize that this may be one 
of the reasons explaining the apparent lack of association 
of submicroscopic infections with adverse outcomes, and 
wide confidence intervals reflect the uncertainty of risk 
estimates. Lastly, women received bed nets, malaria pre-
ventive treatment and close follow-up under trial condi-
tions, thereby limiting generalizability of study findings 
to women receiving routine or no antenatal care.
Conclusions
Microscopy misses at least half of peripheral blood infec-
tions. Submicroscopic infections are common in preg-
nant women, and are hard to diagnose, raising concerns 
about their potential to affect maternal and fetal health. 
In the present study, there was limited evidence that 
these infections are associated with adverse outcomes in 
the context of peripheral infection burden of < 10% and 
provision of bed nets and preventive treatment. Until 
more sensitive diagnostic tools are available, insecticide-
treated bed nets, monthly preventive treatment until 
delivery and detection and treatment of symptomatic 
infections appear appropriate for the management of 
malaria in pregnancy in settings like PNG.
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